Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]

This article refers to:

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases

Menzella F, Lusuardi M, Galeone C, Taddei S, Zucchi L. J Asthma Allergy. 2015;8:105–114.

Page 107, Table 1, Efficacy column, Asthma row, the text “Mepolizumab reduces peripheral blood eosinophilia, percentage of bone marrow eosinophils, airway eosinophils, and rate of exacerbations in almost all RCTs. Improvements in FEV 1 were found in only two studies^13,36” should read “Mepolizumab reduces peripheral blood eosinophilia, percentage of bone marrow eosinophils, airway eosinophils, and rate of exacerbations in almost all RCTs”.

The authors apologize for this error.